Every company has a story. This is ours.
About Adalvo
At Adalvo, we know that our partners like to be bigger, better and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customized and challenges the status quo that helps our partners achieve their business goals.
We are Adalvo
We pride ourselves on helping our partners reach their goals – whether that’s increasing revenues, pushing into new markets – we always play for the high score and to be on target for the partners we serve.
While our clients are our highest priority, we’re also committed to our purpose and our mission to accelerate the growth and development of our employees and local communities.
We are Adalvo – a leading B2B pharmaceutical company.
Our capabilities
Adalvo is the only B2B platform that can offer the following high-value broad portfolio options for its partners as a single business unit.
Generic small-molecule portfolio:
- +40 small-molecule portfolio offering in a wide therapeutic class with a strong focus in Oncology
Value added (505b(2)) portfolio:
- +8 Value added product portfolio offering with a strong focus on CNS
Peptide and biosimilar portfolio:
- +6 Peptide portfolio with a strong focus in Rare Diseases and Diabetes
- +8 Biosimilar portfolio with a strong focus in Immunology and Oncology as well as Ophtalmology
Our locations
Adalvo’s headquarters are in Malta, with additional offices in more than 15 countries such as Switzerland, UK, Netherlands, Spain, Iceland, Austria, Romania, Hungary, Bulgaria, Portugal, Czech Republic, Singapore, China and India.
Dynamic leadership
Our dynamic leadership team brings significant experience and industry know-how to Adalvo that has already established itself as a reliable global partner with commercial partnerships in more than 60 countries and for over 40 commercial partners globally.
Our team is your team
When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward